ADNP and breast cancer: To elucidate the role of AKT in ADNP-induced cycle acceleration and proliferation of BC cells, the AKT-specific inhibitor MK-2206 2HCI was used to treat 5637 and TCCSUP BC cells that overexpressed ADNP.